Science journalism · Not medical advice Regulatory window · PCAC review in 42 days

Peptide reference

DSIP

DSIP

In vitro

First isolated from rabbit cerebral venous blood during induced slow-wave sleep in the 1970s. Small human trials in the 1980s–90s showed reduced stress markers and some sleep architecture effects. The problem: the mechanism isn't clear, the blood-brain barrier penetration is disputed, and endogenous DSIP levels are difficult to measure. Decades of research have produced more questions than answers. It remains on the PCAC July 2026 docket — regulators haven't resolved what to make of it either.

FDA status
No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration.
WADA status
Permitted in sport
Route
subcutaneous injection; intranasal (experimental)

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on DSIP

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where the access actually changes — and where the legitimate supply chain starts to exist.

bpc-157
kpv
tb-500
mots-c
dsip
semax
epithalon

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

bpc-157
kpv
tb-500
mots-c
dsip
semax
epithalon
ghk-cu

DSIP: Delta Sleep-Inducing Peptide Research and the PCAC July 2026 Review

Science-journalism overview of DSIP — the nonapeptide associated with sleep regulation and stress modulation, its evidence base across decades of research, and its position on the PCAC July 23–24 2026 docket.